Possible Link Between Spousal Depressed Mood, Cancer Survivor Quality of Life
the Cancer Therapy Advisor take:
Spousal depressed mood and poor health-related quality of life (HRQoL) may increase the risk of depressed mood and poor HRQoL in cancer survivors, especially female survivors, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
A longitudinal study investigated data from the 2004-2012 Medical Expenditures Panel Survey and another sample of cancer-free dyads.
The data involved reports of depressed mood, psychologic distress, and mental and physical health-related quality of life (HRQoL) from cancer survivors and their spouses (n = 910 dyads). The cancer survivors and their spouses reported these factors at two time points (T1/T2).
The impact of psychosocial factors at T1 on depressed mood at T2 was evaluated by dyadic multilevel models—sociodemographics, cancer type, survivor treatment status, and depressed mood at T1 were all controlled.
Results showed that cancer survivors with spouses who reported depressed mood at T1 were 4.27 times more likely to demonstrate depressed mood at the T2 report (95% CI: 2.01, 9.07].
When spouses reported a better mental and physical HRQoL at T1, there was a 30% decrease in cancer survivor depressed mood at T2.
The study suggests that evaluations should be conducted to see if the incorporation of spousal care into psychooncology and survivorship programs will help improve survivor outcomes.
Spousal depressed mood and poor health-related quality of life may increase risk of depressed mood in cancer survivors.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Arrival of CAR-T Immunotherapy Raise Hopes for Treatment and Anxieties About Costs
- St John's Wort and Cancer
- Osimertinib Granted Breakthrough Therapy Designation as First-line Treatment for EGFR-positive NSCLC
- FDA Grants Priority Review to Afatinib for Uncommon EGFR-positive NSCLC
- Custirsen May Not Improve Survival in Castration-resistant Prostate Cancer
- NSCLC: Researchers Identify Socioeconomic Factors Linked to Overall Survival
- Savolitinib Plus Gefitinib May Be Effective in EGFR-Mutant, MET-amplified NSCLC
- Maintenance Pazopanib Provides PFS, not OS, Benefit in Small-cell Lung Cancer
- Pembrolizumab Plus Pemetrexed, Carboplatin Prolongs Survival in NSCLC
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC